Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xenon Pharmaceuticals (Nasdaq: XENE) has announced equity inducement grants to seven new non-officer employees, totaling 55,300 share options. The options, approved by the Compensation Committee, were granted at an exercise price of $38.60 per common share, matching the closing price on August 28, 2025.
The options vest over four years, with 25% vesting after one year and the remaining vesting monthly over three years. Each option has a 10-year term under the Company's 2025 Inducement Equity Incentive Plan.
Xenon is advancing azetukalner, their lead molecule, in Phase 3 trials for epilepsy, major depressive disorder, and bipolar depression, while also developing early-stage potassium and sodium channel modulators in Phase 1 for pain treatment.
Xenon Pharmaceuticals (Nasdaq: XENE) ha annunciato concessioni di azioni a incentivo per sette nuovi dipendenti non dirigenti, per un totale di 55.300 opzioni su azioni. Le opzioni, approvate dal Compensation Committee, sono state assegnate a un prezzo di esercizio di $38,60 per azione ordinaria, pari al prezzo di chiusura del 28 agosto 2025.
Le opzioni maturano in quattro anni: il 25% dopo il primo anno e la restante parte maturata mensilmente nei tre anni successivi. Ciascuna opzione ha una durata di 10 anni ai sensi del Piano di Incentivazione Azionaria 2025 della Societ脿.
Xenon sta portando avanti azetukalner, la sua molecola principale, in studi di Fase 3 per l鈥檈pilessia, il disturbo depressivo maggiore e la depressione bipolare, e sta inoltre sviluppando modulatori dei canali del potassio e del sodio in Fase 1 per il trattamento del dolore.
Xenon Pharmaceuticals (Nasdaq: XENE) ha anunciado concesiones de incentivos en acciones a siete nuevos empleados no ejecutivos, por un total de 55.300 opciones sobre acciones. Las opciones, aprobadas por el Comit茅 de Compensaci贸n, se otorgaron a un precio de ejercicio de $38,60 por acci贸n ordinaria, igual al precio de cierre del 28 de agosto de 2025.
Las opciones se consolidan en un periodo de cuatro a帽os: el 25% despu茅s del primer a帽o y el resto de forma mensual durante los tres a帽os siguientes. Cada opci贸n tiene un plazo de 10 a帽os conforme al Plan de Incentivos de Capital de Admisi贸n 2025 de la Compa帽铆a.
Xenon est谩 avanzando azetukalner, su mol茅cula principal, en ensayos de Fase 3 para epilepsia, trastorno depresivo mayor y depresi贸n bipolar, y adem谩s desarrolla moduladores de canales de potasio y sodio en Fase 1 para el tratamiento del dolor.
Xenon Pharmaceuticals (Nasdaq: XENE)電� 牍勳瀯鞗� 鞁犾瀰 歆侅洂 7氇呾棎瓴� 齑� 55,300欤� 鞓奠厴鞚� 欤检嫕 鞚胳劶韹半笇毳� 攵�鞐枅雼り碃 氚滍憸頄堨姷雼堧嫟. 氤挫儊鞙勳洂須岅皜 鞀轨澑頃� 鞚� 鞓奠厴鞚� 2025雲� 8鞗� 28鞚� 膦呹皜鞕� 霃欖澕頃� 欤茧嫻 $38.60鞚� 頄夓偓臧�搿� 攵�鞐悩鞐堨姷雼堧嫟.
鞓奠厴鞚� 4雲� 霃欖晥 氩犾姢韺呺悩氅�, 1雲� 頉� 25%臧� 氩犾姢韸鸽悩瓿� 雮橂ǜ歆�電� 鞚错泟 3雲� 霃欖晥 毵れ洈 氩犾姢韺呺惄雼堧嫟. 臧� 鞓奠厴鞚� 鞙犿毃旮瓣皠鞚� 須岇偓鞚� 2025 鞚鸽崟靺� 欤检嫕 鞚胳劶韹半笇 頂岆灉鞐� 霐半澕 10雲勳瀰雼堧嫟.
Xenon鞚� 欤检殧 氍检鞚� azetukalner毳� 臧勳, 欤检殧鞖办毟鞛レ暊 氚� 鞏戧饭靹� 鞖办毟歃濎棎 雽�頃� 3靸� 鞁滍棙鞙茧 歆勴枆 欷戩澊氅�, 韱奠 旃橂毳� 鞙勴暣 旃茧エ 氚� 雮橅姼毳� 毂勲剱 臁办爤鞝滊弰 1靸侅棎靹� 臧滊皽頃橁碃 鞛堨姷雼堧嫟.
Xenon Pharmaceuticals (Nasdaq: XENE) a annonc茅 des attributions d鈥檌ncitations en actions 脿 sept nouveaux employ茅s non-dirigeants, pour un total de 55 300 options d鈥檃ction. Les options, approuv茅es par le comit茅 de r茅mun茅ration, ont 茅t茅 accord茅es 脿 un prix d鈥檈xercice de 38,60 $ par action ordinaire, correspondant au cours de cl么ture du 28 ao没t 2025.
Les options acqui猫rent des droits sur quatre ans : 25 % au bout d鈥檜n an, le solde acqu茅rant mensuellement sur les trois ann茅es suivantes. Chaque option a une dur茅e de 10 ans en vertu du Plan d鈥檌ncitation en actions 2025 de la Soci茅t茅.
Xenon fait progresser azetukalner, sa mol茅cule principale, en essais de phase 3 pour l鈥櫭﹑ilepsie, le trouble d茅pressif majeur et la d茅pression bipolaire, et d茅veloppe par ailleurs des modulateurs des canaux potassiques et sodiques en phase 1 pour le traitement de la douleur.
Xenon Pharmaceuticals (Nasdaq: XENE) hat Aktienanreiz-Zuteilungen an sieben neue Nicht-F眉hrungsmitarbeiter angek眉ndigt, insgesamt 55.300 Aktienoptionen. Die vom Verg眉tungsausschuss genehmigten Optionen wurden zu einem Aus眉bungspreis von $38,60 je Stammaktie gew盲hrt, entsprechend dem Schlusskurs vom 28. August 2025.
Die Optionen vesten 眉ber vier Jahre: 25% nach einem Jahr, der Rest vestet monatlich 眉ber die folgenden drei Jahre. Jede Option hat eine Laufzeit von 10 Jahren gem盲脽 dem Inducement Equity Incentive Plan 2025 des Unternehmens.
Xenon treibt azetukalner, seinen f眉hrenden Wirkstoff, in Phase-3-Studien bei Epilepsie, Major Depression und bipolarer Depression voran und entwickelt zudem in Phase 1 Kalium- und Natriumkanalmodulatoren zur Schmerzlinderung.
- Company is expanding its workforce with seven new hires
- Lead drug candidate azetukalner is advancing in Phase 3 clinical trials for multiple indications
- Multiple early-stage programs in development for pain treatment
- Share options will result in dilution for existing shareholders
VANCOUVER, British Columbia and BOSTON, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc.聽(Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to seven new non-officer employees consisting of an aggregate of 55,300 share options. All of the foregoing share options were approved by the Compensation Committee of the Company鈥檚 Board of Directors with an effective date of聽August 28, 2025聽and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
The share options have an exercise price of聽
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals聽(Nasdaq: XENE) is a neuroscience-focused聽biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. Xenon鈥檚 lead molecule, azetukalner, is a novel, potent, selective Kv7 potassium channel opener in Phase 3 clinical trials for the treatment of epilepsy, major depressive disorder (MDD) and bipolar depression (BPD). Xenon is also advancing an early-stage portfolio of multiple promising potassium and sodium channel modulators, including Kv7 and Nav1.7 programs in Phase 1 development for the potential treatment of pain. Xenon has offices in聽Vancouver, British Columbia, and聽Boston, Massachusetts. For more information, visit聽聽and follow us on聽听补苍诲听.
鈥淴enon鈥� and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Contact:
Colleen Alabiso
Senior Vice President, Corporate Affairs
(617) 671-9238
Media:
Investors:
FAQ
What equity grants did Xenon Pharmaceuticals (XENE) announce in August 2025?
What is the vesting schedule for XENE's August 2025 inducement grants?
What is Xenon Pharmaceuticals' (XENE) lead drug candidate?
What therapeutic areas is Xenon Pharmaceuticals (XENE) focusing on?
